UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053154
Receipt number R000058961
Scientific Title Exploratory analysis of gut microbiome as a novel biomarker in patients with advanced thymic carcinoma on immunochemotherapy
Date of disclosure of the study information 2023/12/19
Last modified on 2023/12/19 12:58:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory analysis of gut microbiome as a novel biomarker in patients with advanced thymic carcinoma on immunochemotherapy

Acronym

NCCH2109A

Scientific Title

Exploratory analysis of gut microbiome as a novel biomarker in patients with advanced thymic carcinoma on immunochemotherapy

Scientific Title:Acronym

NCCH2109A

Region

Japan


Condition

Condition

thymic carcinoma

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To explore biomarkers useful in predicting the outcome of treatment with carboplatin + paclitaxel + pembrolizumab + lenvatinib for untreated unresectable thymic carcinoma.

Basic objectives2

Others

Basic objectives -Others

none

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Whether the composition of the intestinal flora is a predictive factor

Key secondary outcomes

Whether plasma biomarkers are predictive factors


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Written consent to participate in this accessory study has been obtained prior to the start of protocol treatment in the main study (NCCH2109).

Key exclusion criteria

none

Target sample size

35


Research contact person

Name of lead principal investigator

1st name Yusuke
Middle name
Last name Okuma

Organization

National Cancer Center Hospital

Division name

Department of thoracic oncology

Zip code

104-0045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Email

ncch2109_jimukyoku@is-pc.or.jp


Public contact

Name of contact person

1st name Yusuke
Middle name
Last name Okuma

Organization

National Cancer Center Hospital

Division name

Department of thoracic oncology

Zip code

104-0045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Homepage URL


Email

ncch2109_jimukyoku@is-pc.or.jp


Sponsor or person

Institute

Yusuke Okuma, National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

pending

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center Institutional Review Board

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

Tel

03-3542-2511

Email

irst@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 26 Day

Date of IRB

2023 Year 11 Month 08 Day

Anticipated trial start date

2024 Year 01 Month 04 Day

Last follow-up date

2027 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

none


Management information

Registered date

2023 Year 12 Month 19 Day

Last modified on

2023 Year 12 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058961


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name